HC Wainwright Reaffirms “Neutral” Rating for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Other equities analysts have also recently issued research reports about the stock. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Canaccord Genuity Group cut their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Trading Down 10.3 %

Shares of ATRA stock opened at $7.37 on Tuesday. Atara Biotherapeutics has a 1 year low of $5.40 and a 1 year high of $39.50. The firm’s fifty day simple moving average is $11.89 and its 200 day simple moving average is $9.96. The firm has a market capitalization of $42.45 million, a P/E ratio of -0.29 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the business earned ($16.50) earnings per share. Equities research analysts anticipate that Atara Biotherapeutics will post -9.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATRA. Vestal Point Capital LP increased its position in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the period. Geode Capital Management LLC increased its position in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares in the last quarter. FMR LLC grew its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the period. State Street Corp grew its position in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics during the second quarter worth $79,000. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.